Tekla Healthcare Investors logo

Tekla Healthcare Investors(HQH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
3-STAR RATING
PASS
LAST CLOSE
$21.43
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HQH

11/13/2026: HQH (3-star) is currently NOT-A-BUY. Pass it for now.

Tekla Healthcare Investors is a closed-end investment fund that provides exposure to a professionally managed portfolio of healthcare, biotechnology, and medical device companies. The fund's primary strengths lie in its specialized domain expertise, diversified life sciences holdings, and consistent managed distribution policies that appeal to income-oriented investors. Its core growth story centers on capturing technological breakthroughs and potential M&A catalysts within emerging medical fields. However, the fund faces risks related to clinical trial volatility, healthcare regulatory pressures, and fluctuations in market valuation relative to net asset value. It is best suited for growth and dividend investors comfortable with single-sector equity volatility, who should monitor ongoing portfolio clinical milestones and broader biotechnology market trends.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe fund targets capital appreciation through high-growth biotechnology and healthcare equities.
Momentum investorStrong fit while signal remains positiveBiotechnology holdings can experience sharp upward momentum during favorable clinical trial and M&A cycles.
Value investorMixed fitShares occasionally trade at discounts to net asset value, though underlying holdings are growth-oriented.
Dividend investorStrong fitThe fund utilizes a managed distribution policy delivering high recurring payout yields.
Low-risk investorWeak fitSingle-sector concentration in healthcare and biotechnology introduces elevated volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotechnology and emerging medical stocks experience sharp price swings.
Valuation riskMediumFund shares can trade at varying premiums or discounts relative to underlying net asset value.
Competition risk (sector and fund competition)MediumThe fund competes with numerous healthcare vehicles and alternative investment options for capital.
Business qualityMedium / highPortfolio selection leverages professional analysis of top-tier medical and biotech innovators.
Dividend incomeMediumDistributions depend on realized capital gains and portfolio performance rather than fixed operating earnings.
Execution riskMediumSuccess relies heavily on the portfolio management team's ability to select winning healthcare equities.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.23B USD
Price to earnings Ratio 4.79
1Y Target Price -
Price to earnings Ratio 4.79
1Y Target Price -
Volume (30-day avg) 179.6K shares
Beta 0.74
52 Weeks Range 16.17 - 24.18
Updated Date 11/15/2026
52 Weeks Range 16.17 - 24.18
Updated Date 11/15/2026
Dividends yield (FY) 10.55%
Basic EPS (TTM) 4.47

Sector & Industry Intelligence

Sector

Financial Services

Constructive
Sentiment
Bullish
Momentum
BUY Breadth Improving
BUY participation
50.4%
Active BUY / eligible
61 / 121
30-Day BUY Count Change
+45
Market state
Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Asset Management

BUY participation
52.9%
Active BUY / eligible
9 / 17
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit 74.62%
Avg. Invested days 102
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 5.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HQH receives a 3-star rating based on the available scored pillars. The rating is constrained by soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
HQH has moderate overall fundamentals (3 stars), with solid financial health, moderate growth momentum, and soft ownership. In FY2025 versus FY2024, strong revenue growth (+826.8%) and strong profitability (net margin 98.8%) are partially offset by negative earnings growth (-46.7%), soft cash generation (FCF margin 0.0%), very low insider ownership of 0.00%.

Financial Health Rating

★★★★★
HQH's financial health is supported by strong profitability, including gross margin of 100.0% and operating margin of 98.8%. Liquidity is soft (2 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is HQH's strongest growth driver at +826.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-46.7%, negative) and free-cash-flow growth (+0.0%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 24.1% (moderate) and 0.0% of outstanding shares are publicly tradable (soft). Insider ownership is only 0.00%, which materially reduces the ownership score.

Unit Economics (Per $1K Revenue)

★★★★★
HQH generates approximately $1,000 of gross profit, $988 of operating income, and $0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and weak cash conversion support a 3-star rating, while capital efficiency is soft.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
HQH has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Investment Portfolio ReturnsCapital appreciation, dividends, and realized gains from holdings in biotechnology, pharmaceuticals, and medical device companies.You make money when the fund's underlying healthcare stocks increase in value and distribute payouts.

Valuation

Trailing PE 4.79
Forward PE -
Enterprise Value 1.06B
Price to Sales(TTM) 5.46
Enterprise Value 1.06B
Price to Sales(TTM) 5.46
Enterprise Value to Revenue 4.83
Enterprise Value to EBITDA -
Shares Outstanding 57.19M
Shares Floating -
Shares Outstanding 57.19M
Shares Floating -
Percent Insiders -
Percent Institutions 24.12

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.